Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
暂无分享,去创建一个
[1] M. V. D. van den Brink,et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. , 2001, Blood.
[2] J. Melo,et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. , 2001, Blood.
[3] P. Krammer,et al. TCR-Mediated Up-Regulation of c-FLIPshort Correlates with Resistance Toward CD95-Mediated Apoptosis by Blocking Death-Inducing Signaling Complex Activity1 , 2000, The Journal of Immunology.
[4] J. Goldman,et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.
[5] H. Stauss,et al. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. , 1999, Blood.
[6] W. M. Smit,et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.
[7] J. Gribben,et al. Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.
[8] V. Calcaterra,et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.
[9] H. Prentice,et al. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.
[10] Y. Aizawa,et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation , 1999 .
[11] R. Siegel,et al. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.
[12] R. Noelle,et al. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. , 1998, The Journal of clinical investigation.
[13] J. Crawford,et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.
[14] N. Young,et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect , 1998, Bone Marrow Transplantation.
[15] S. Dowdy,et al. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. , 1998, Immunity.
[16] G. Szot,et al. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. , 1997, Blood.
[17] C. Bordignon,et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.
[18] D. Green,et al. Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis , 1997, The Journal of experimental medicine.
[19] D. Klatzmann,et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. , 1997, Blood.
[20] N. Hensel,et al. Preferential usage of T cell receptor (TCR) V β by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease , 1997, Bone Marrow Transplantation.
[21] E. Podack,et al. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[22] K. Elkon,et al. A major role for the Fas pathway in acute graft-versus-host disease. , 1996, Journal of immunology.
[23] K. Parker,et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.
[24] J. Ferrara,et al. The Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease , 1996, Stem cells.
[25] A. Abbas,et al. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. , 1996, Immunity.
[26] J. Ferrara,et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. , 1995, Journal of immunology.
[27] Seamus J. Martin,et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.
[28] P. Krammer,et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.
[29] M. Eckhaus,et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. , 1994, Blood.
[30] A. Barrett,et al. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. , 1994, Bone marrow transplantation.
[31] S. Riddell,et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.
[32] S. Nagata,et al. Lethal effect of the anti-Fas antibody in mice , 1993, Nature.
[33] P. Martin,et al. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans , 1993, The Journal of experimental medicine.
[34] P. Krammer,et al. Activation interferes with the APO-1 pathway in mature human T cells. , 1993, International immunology.
[35] H. Heimpel,et al. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. , 1992, The New England journal of medicine.
[36] M. Lenardo. lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.
[37] D. Loh,et al. Receptor-stimulated death pathway is opened by antigen in mature T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. Lenardo. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. , 1991, Nature.
[39] A. Heimberger,et al. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. , 1990, Science.
[40] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[41] M. Zutter,et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. , 1988, Blood.
[42] R. Hoffmann,et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .